Page 780 - Coronavirus Vaccine

Global coronavirus tally rises by record 3.6 million in week: WHO

The death toll rose by over 54,000 over the same period

Covid-19 active tally falls below 500,000 for first time in 106 days

Twenty-seven states and UTs have less than 20,000 active cases, the ministry highlighted

Global coronavirus tally rises by record 3.6 million in a week: WHO

The number of confirmed coronavirus cases climbed by a record 3.6 million globally last week, the World Health Organization (WHO) has said.As of November 8, the global tally totaled over 49.7 million cases, which is 8 per cent more compared to the previous week.The death toll rose by over 54,000 over the same period.The previous all-time high of over 3.3 million infections was recorded in the week from October 26 to November 1.

Govt needs to define Covid-19 vaccine distribution strategy: Rahul Gandhi

Pfizer Inc and BioNTech SE have said that their vaccine candidate has been found to be more than 90 per cent effective in preventing COVID-19

Divi's Lab, Aurobindo Pharma: Are pharma stocks losing their sheen? Read on

Till Nifty Pharma holds above the 11,180 mark, the bullish bias will prevail, charts suggest.

New 'hidden' coronavirus gene identified, could help in developing vaccine

knowing more about the 15 genes that make up the coronavirus genome could have a significant impact on developing drugs and vaccines to combat the virus

32 security personnel among 97 new Covid-19 patients in Arunachal

The IRB jawans are among the 641 security personnel who returned from Bihar on Tuesday after election duty, the official said

India's Covid-19 tally crosses 8.6 million mark, recovery rises to 92.79%

The number of people who have recuperated from the disease surged to 80.13 lakh, pushing the national recovery rate to 92.79 per cent, according to the Union Health Ministry's data

Five questions you should be asking about Pfizer's coronavirus vaccine

Important scientific announcements are usually made through peer-reviewed medical research papers, not company press releases

EU to buy up to 300 million doses of Pfizer-BioNTech Covid-19 vaccine

The European Commission will sign a deal to secure up to 300 million doses of the experimental coronavirus vaccine developed by BioNTech and Pfizer

US: WHO not sharing enough info about plans to investigate origin of virus

Some scientists worry that China has still not provided key details about what research is already ongoing

US reports 1 million new coronavirus cases in a month, death toll soaring

The tally of cases in just 10 days shows the reach of the virus amid a strong fall surge

For companies like Zoom and Netflix, a Covid-19 vaccine dampens prospects

Shares in video conferencing network Zoom fell 4% on Tuesday after plunging about 17% a day earlier

UK records highest daily Covid-19 death toll since mid-May, toll at 49,770

20,412 people have tested positive for Covid-19, bringing the total number of cases in the country to 1,233,775, the data showed

Brazil halting coronavirus vaccine CoronaVac trial surprises the world

The potential vaccine is being developed by Chinese biopharmaceutical firm Sinovac and in Brazil would be mostly produced by Sao Paulo's state-run Butantan Institute

Advancing our dialogue with India for Covid-19 vaccine, says Pfizer

Pfizer is committed to ensure the availability of its Covid vaccine for use by governments across the world.

India capable of strengthening cold chain for Pfizer vaccine: Health secy

Rajesh Bhushan was responding to a query on the country's cold storage capacity for vaccines such as Pfizer's that need to be kept in minus 70 degree celsius

EU plans to buy up to 300 million doses of Pfizer-BioNTech vaccine

Ursula von der Leyen, the president of the EU's executive arm, said the commission will authorize the deal on Wednesday after working tirelessly to secure doses of potential vaccines in recent months

Eli Lilly's Covid-19 antibody drug treatment gets emergency USFDA clearance

The FDA authorised the experimental treatment, called bamlanivimab, for use against mild-to-moderate Covid-19 in adults, including those who are 65 and older, and pediatric patients

BioNTech to price vaccine below market rates, differentiate between regions

Ryan Richardson said the price tag of the vaccine